Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain. Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.

AbbVie is also currently conducting a Phase II study of elagolix for uterine fibroids to assess blood loss in women with heavy uterine bleeding due to such fibroids. AbbVie expects a Phase IIb study in uterine fibroids to commence in 2013.

VMAT2 UpdateThe Company is currently conducting two Phase IIb studies of its VMAT2 inhibitor NBI-98854.

The Kinect Study is a 120 subject, placebo-controlled, double-blind, parallel design, multiple dose, 12-week study assessing six-week dosing of NBI-98854 against placebo, followed by six weeks of open-label treatment with NBI-98854. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the first six weeks of dosing. The study will also incorporate a capsule formulation of NBI-98854. Top-line data from the placebo-controlled portion of this study is expected in the second quarter of 2013.

The Kinect 2 Study is a 90 subject, placebo-controlled, double-blind, parallel design, multiple dose, six-week study assessing NBI-98854 against placebo. The primary endpoint is the AIMS at the end of the six weeks of dosing. Top-line data from this placebo-controlled study is expected in the third quarter of 2013.

Additionally, the Company is conducting appropriate preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome.

The Company anticipates and end-of-phase-II meeting for NBI-98854 in tardive dyskinesia to be held with the FDA in the fourth quarter of 2013.

Conference Call and Webcast Today at 8:00 AM Eastern Time
Neurocrine will hold a live conference call and webcast today at 8:00 a
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...   SurePure, Inc . (OTCQB: SURP), a ... the Company has completed the verification process and ... ("SURP") securities on OTCQB, an electronic quote and ... stage companies. On March 26, 2014, ... designed to improve marketplace integrity and enhance transparency ...
(Date:3/27/2015)... 27, 2015 WuXi PharmaTech (Cayman) Inc. ... capability and technology platform company serving the global ... that an Investigational New Drug (IND) application for ... arthritis has been accepted for review by the ... In September 2012, MedImmune, the global biologics ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2
... , , COLUMBIA, Md., Sept. 8 ... that a panel of judges on the United States Court of ... appeal proceedings related to a patent infringement lawsuit between Martek and ... GmbH (collectively "Lonza"). The appeals involve Lonza,s U.S. sale and ...
... , PRINCETON, N.J., Sept. 8 Pharmasset, Inc. ... the Robert W. Baird & Co. Health Care Conference, Morgan ... Sciences Conference in New York, NY and the ThinkEquity G6 ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will ...
... , FORT LAUDERDALE, Fla., Sept. 8 ... in the region, launched an important joint event with the state,s ... gathered in Fort Lauderdale on August 27, to hear experts from ... of bio science and information technology. , , ...
Cached Biology Technology:Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 2Federal Circuit Rules in Martek's Favor in Appeal of Patent Infringement Case 3Pharmasset to Present at Four Upcoming Investor Conferences 2Pharmasset to Present at Four Upcoming Investor Conferences 3South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 2South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 3
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... of Pennsylvania School of Medicine have clarified the mechanism ... problems, in multiple animal models. The findings offer the ... bypass this issue, as reported in the April 13 ... Journal of Clinical Investigation. , "Although these results are ...
... at an alarming rate throughout Britain's coast and rivers, ... crab, brought to Britain during the last century in ... populations are not monitored and controlled, say the study's ... upon Tyne carried out the first comprehensive modelling of ...
... from the Max Planck Institite for Biophysical Chemistry ... magnetic resonance spectroscopy (solid-state NMR) with special protein ... toxins combine and change in structure. This work ... high blood pressure and many other diseases connected ...
Cached Biology News:Therapeutic prospects beyond Vioxx 2Therapeutic prospects beyond Vioxx 3Exotic crab poised for widespread UK invasion 2Exotic crab poised for widespread UK invasion 3Unraveling the mysteries of poison 2
... leader in electroporation products and specialty electrodes, ... line for experiment optimization and large volume ... breakthrough in Molecular Delivery. The days of ... typically limited the number of samples and ...
... Endogens Screening Sets contain the ... develop five colorimetric sandwich ELISA plates ... in 100 l/well of cell culture ... and Detection Antibodies, Recombinant Standard (5 ...
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP). ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently tagged ...
... The organic acid analysis standard ... six organic salts; molecular weights ... This standard is provided for ... column and the organic acid ...
Biology Products: